This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Effectiveness of UVA1-irradiation in the Treatment of Early Skin Fibrosis in Patients Suffering From Systemic Sclerosis

This study has been terminated.
(lack of recruitement)
Sponsor:
Collaborator:
University Hospital Tuebingen
Information provided by (Responsible Party):
Nicolas Hunzelmann, University of Cologne
ClinicalTrials.gov Identifier:
NCT00628797
First received: February 26, 2008
Last updated: May 29, 2017
Last verified: May 2017
  Purpose
Systemic scleroderma (SSc) is a rare chronic inflammatory diseae of the connective tissue involving the skin and internal organs. To date there is no proven therapy for the skin fibrosis available. A number of case reports and small uncontrolled cohort studies suggest that UVA1 therapy may improve skin fibrosis. The aim of this study is therefore to investigate whether treatment UVA1 in deed is effective in treating skin fibrosis in SSc using a randomized, intraindividual half body irradiation protocol.

Condition Intervention Phase
Systemic Scleroderma Systemic Sclerosis Radiation: UVA1 Other: UVA1 Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multizenter-Studie Zur UVA-1 Therapie für Die Hautbeteiligung Bei Systemischer Sklerodermie

Resource links provided by NLM:


Further study details as provided by Nicolas Hunzelmann, University of Cologne:

Primary Outcome Measures:
  • modified skin score [ Time Frame: 3 months ]

Secondary Outcome Measures:
  • modified skin score [ Time Frame: 6 months ]
  • histologic examination [ Time Frame: 3 months ]

Enrollment: 9
Study Start Date: February 2008
Study Completion Date: November 2013
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
A UVA1 B no UVA1
half body irradiation with random allocation right and left; after three months of treatment treatment of both sides
Other: UVA1
60 J/cm2 at least 36 tx
Other Name: Ultraviolet light
Experimental: A UVA1 Radiation: UVA1
intraindividual half body irradiation
Other Name: ultraviolet light
Other: UVA1
60 J/cm2 at least 36 tx
Other Name: Ultraviolet light

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • systemic sclerosis ACR criteria
  • skin fibrosis at least involving the distal third of the lower arm

Exclusion Criteria:

  • photosensitizing drugs
  • recent UV therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00628797

Locations
Germany
University of Tuebingen, Dept. of Dermatology
Tuebingen, BW, Germany, 72076
University of Cologne, Dept. of Dermatology
Cologne, NRW, Germany, 50937
Sponsors and Collaborators
Nicolas Hunzelmann
University Hospital Tuebingen
Investigators
Principal Investigator: Nicolas Hunzelmann University of Cologne, Dept. of Dermatology
  More Information

Responsible Party: Nicolas Hunzelmann, Prof. Dr. N. Hunzelmann, University of Cologne
ClinicalTrials.gov Identifier: NCT00628797     History of Changes
Other Study ID Numbers: 07-200
Study First Received: February 26, 2008
Last Updated: May 29, 2017

Keywords provided by Nicolas Hunzelmann, University of Cologne:
systemic sclerosis
skin fibrosis

Additional relevant MeSH terms:
Sclerosis
Scleroderma, Systemic
Scleroderma, Diffuse
Pathologic Processes
Connective Tissue Diseases
Skin Diseases

ClinicalTrials.gov processed this record on September 21, 2017